FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290793764> ?p ?o ?g. }

• W4290793764 endingPage "554" @default.
• W4290793764 startingPage "554" @default.
• W4290793764 abstract "<h3>Importance</h3> The role of ticagrelor with or without aspirin after coronary artery bypass graft surgery remains unclear. <h3>Objective</h3> To compare the risks of vein graft failure and bleeding associated with ticagrelor dual antiplatelet therapy (DAPT) or ticagrelor monotherapy vs aspirin among patients undergoing coronary artery bypass graft surgery. <h3>Data Sources</h3> MEDLINE, Embase, and Cochrane Library databases from inception to June 1, 2022, without language restriction. <h3>Study Selection</h3> Randomized clinical trials (RCTs) comparing the effects of ticagrelor DAPT or ticagrelor monotherapy vs aspirin on saphenous vein graft failure. <h3>Data Extraction and Synthesis</h3> Individual patient data provided by each trial were synthesized into a combined data set for independent analysis. Multilevel logistic regression models were used. <h3>Main Outcomes and Measures</h3> The primary analysis assessed the incidence of saphenous vein graft failure per graft (primary outcome) in RCTs comparing ticagrelor DAPT with aspirin. Secondary outcomes were saphenous vein graft failure per patient and Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding events. A supplementary analysis included RCTs comparing ticagrelor monotherapy with aspirin. <h3>Results</h3> A total of 4 RCTs were included in the meta-analysis, involving 1316 patients and 1668 saphenous vein grafts. Of the 871 patients in the primary analysis, 435 received ticagrelor DAPT (median age, 67 years [IQR, 60-72 years]; 65 women [14.9%]; 370 men [85.1%]) and 436 received aspirin (median age, 66 years [IQR, 61-73 years]; 63 women [14.5%]; 373 men [85.5%]). Ticagrelor DAPT was associated with a significantly lower incidence of saphenous vein graft failure (11.2%) per graft than was aspirin (20%; difference, −8.7% [95% CI, −13.5% to −3.9%]; OR, 0.51 [95% CI, 0.35 to 0.74];<i>P</i> < .001) and was associated with a significantly lower incidence of saphenous vein graft failure per patient (13.2% vs 23.0%, difference, −9.7% [95% CI, −14.9% to −4.4%]; OR, 0.51 [95% CI, 0.35 to 0.74];<i>P</i> < .001). Ticagrelor DAPT (22.1%) was associated with a significantly higher incidence of BARC type 2, 3, or 5 bleeding events than was aspirin (8.7%; difference, 13.3% [95% CI, 8.6% to 18.0%]; OR, 2.98 [95% CI, 1.99 to 4.47];<i>P</i> < .001), but not BARC type 3 or 5 bleeding events (1.8% vs 1.8%, difference, 0% [95% CI, −1.8% to 1.8%]; OR, 1.00 [95% CI, 0.37 to 2.69];<i>P</i> = .99). Compared with aspirin, ticagrelor monotherapy was not significantly associated with saphenous vein graft failure (19.3% vs 21.7%, difference, −2.6% [95% CI, −9.1% to 3.9%]; OR, 0.86 [95% CI, 0.58 to 1.27];<i>P</i> = .44) or BARC type 2, 3, or 5 bleeding events (8.9% vs 7.3%, difference, 1.7% [95% CI, −2.8% to 6.1%]; OR, 1.25 [95% CI, 0.69 to 2.29];<i>P</i> = .46). <h3>Conclusions and Relevance</h3> Among patients undergoing coronary artery bypass graft surgery, adding ticagrelor to aspirin was associated with a significantly decreased risk of vein graft failure. However, this was accompanied by a significantly increased risk of clinically important bleeding." @default.
• W4290793764 created "2022-08-09" @default.
• W4290793764 creator A5000045667 @default.
• W4290793764 creator A5003407473 @default.
• W4290793764 creator A5006033711 @default.
• W4290793764 creator A5015994263 @default.
• W4290793764 creator A5016139987 @default.
• W4290793764 creator A5026877561 @default.
• W4290793764 creator A5027517032 @default.
• W4290793764 creator A5040418600 @default.
• W4290793764 creator A5044824813 @default.
• W4290793764 creator A5049805549 @default.
• W4290793764 creator A5053178157 @default.
• W4290793764 creator A5062850057 @default.
• W4290793764 creator A5065626931 @default.
• W4290793764 creator A5066672681 @default.
• W4290793764 creator A5076258810 @default.
• W4290793764 creator A5078909594 @default.
• W4290793764 creator A5078997813 @default.
• W4290793764 creator A5089531607 @default.
• W4290793764 date "2022-08-09" @default.
• W4290793764 modified "2023-10-10" @default.
• W4290793764 title "Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery" @default.
• W4290793764 cites W2050118439 @default.
• W4290793764 cites W2122779695 @default.
• W4290793764 cites W2336744020 @default.
• W4290793764 cites W2765697464 @default.
• W4290793764 cites W2786466689 @default.
• W4290793764 cites W2800245419 @default.
• W4290793764 cites W2891132859 @default.
• W4290793764 cites W2916912835 @default.
• W4290793764 cites W2970684805 @default.
• W4290793764 cites W2970797239 @default.
• W4290793764 cites W2970970966 @default.
• W4290793764 cites W2977745968 @default.
• W4290793764 cites W2979960612 @default.
• W4290793764 cites W3082585947 @default.
• W4290793764 cites W3148629439 @default.
• W4290793764 cites W3196719801 @default.
• W4290793764 cites W4200210946 @default.
• W4290793764 cites W4200601666 @default.
• W4290793764 cites W4212868194 @default.
• W4290793764 cites W4220973559 @default.
• W4290793764 cites W4225526112 @default.
• W4290793764 cites W4236067666 @default.
• W4290793764 doi "https://doi.org/10.1001/jama.2022.11966" @default.
• W4290793764 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35943473" @default.
• W4290793764 hasPublicationYear "2022" @default.
• W4290793764 type Work @default.
• W4290793764 citedByCount "24" @default.
• W4290793764 countsByYear W42907937642022 @default.
• W4290793764 countsByYear W42907937642023 @default.
• W4290793764 crossrefType "journal-article" @default.
• W4290793764 hasAuthorship W4290793764A5000045667 @default.
• W4290793764 hasAuthorship W4290793764A5003407473 @default.
• W4290793764 hasAuthorship W4290793764A5006033711 @default.
• W4290793764 hasAuthorship W4290793764A5015994263 @default.
• W4290793764 hasAuthorship W4290793764A5016139987 @default.
• W4290793764 hasAuthorship W4290793764A5026877561 @default.
• W4290793764 hasAuthorship W4290793764A5027517032 @default.
• W4290793764 hasAuthorship W4290793764A5040418600 @default.
• W4290793764 hasAuthorship W4290793764A5044824813 @default.
• W4290793764 hasAuthorship W4290793764A5049805549 @default.
• W4290793764 hasAuthorship W4290793764A5053178157 @default.
• W4290793764 hasAuthorship W4290793764A5062850057 @default.
• W4290793764 hasAuthorship W4290793764A5065626931 @default.
• W4290793764 hasAuthorship W4290793764A5066672681 @default.
• W4290793764 hasAuthorship W4290793764A5076258810 @default.
• W4290793764 hasAuthorship W4290793764A5078909594 @default.
• W4290793764 hasAuthorship W4290793764A5078997813 @default.
• W4290793764 hasAuthorship W4290793764A5089531607 @default.
• W4290793764 hasBestOaLocation W42907937642 @default.
• W4290793764 hasConcept C126322002 @default.
• W4290793764 hasConcept C141071460 @default.
• W4290793764 hasConcept C164705383 @default.
• W4290793764 hasConcept C168563851 @default.
• W4290793764 hasConcept C2775901492 @default.
• W4290793764 hasConcept C2776820930 @default.
• W4290793764 hasConcept C2777628954 @default.
• W4290793764 hasConcept C2777849778 @default.
• W4290793764 hasConcept C2780890252 @default.
• W4290793764 hasConcept C71924100 @default.
• W4290793764 hasConceptScore W4290793764C126322002 @default.
• W4290793764 hasConceptScore W4290793764C141071460 @default.
• W4290793764 hasConceptScore W4290793764C164705383 @default.
• W4290793764 hasConceptScore W4290793764C168563851 @default.
• W4290793764 hasConceptScore W4290793764C2775901492 @default.
• W4290793764 hasConceptScore W4290793764C2776820930 @default.
• W4290793764 hasConceptScore W4290793764C2777628954 @default.
• W4290793764 hasConceptScore W4290793764C2777849778 @default.
• W4290793764 hasConceptScore W4290793764C2780890252 @default.
• W4290793764 hasConceptScore W4290793764C71924100 @default.
• W4290793764 hasIssue "6" @default.
• W4290793764 hasLocation W42907937641 @default.
• W4290793764 hasLocation W42907937642 @default.
• W4290793764 hasLocation W42907937643 @default.
• W4290793764 hasOpenAccess W4290793764 @default.
• W4290793764 hasPrimaryLocation W42907937641 @default.

• next